Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.
2.

ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.

Lee SY, Shin SJ, Kim HS.

Int J Oncol. 2013 Mar;42(3):1027-35. doi: 10.3892/ijo.2013.1764. Epub 2013 Jan 10.

PMID:
23314357
4.

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.

Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, Der CJ.

Mol Cancer Ther. 2009 Apr;8(4):834-43. doi: 10.1158/1535-7163.MCT-08-0972.

5.

Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover.

Lim JH, Liu Y, Reineke E, Kao HY.

J Biol Chem. 2011 Dec 30;286(52):44403-11. doi: 10.1074/jbc.M111.289512. Epub 2011 Oct 27.

6.

ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells.

Sarközi R, Miller B, Pollack V, Feifel E, Mayer G, Sorokin A, Schramek H.

J Cell Physiol. 2007 Apr;211(1):88-100.

PMID:
17131384
8.

Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2.

Kauppinen TM, Chan WY, Suh SW, Wiggins AK, Huang EJ, Swanson RA.

Proc Natl Acad Sci U S A. 2006 May 2;103(18):7136-41. Epub 2006 Apr 20.

9.

Ras/mitogen-activated protein kinase (MAPK) signaling modulates protein stability and cell surface expression of scavenger receptor SR-BI.

Wood P, Mulay V, Darabi M, Chan KC, Heeren J, Pol A, Lambert G, Rye KA, Enrich C, Grewal T.

J Biol Chem. 2011 Jul 1;286(26):23077-92. doi: 10.1074/jbc.M111.236398. Epub 2011 Apr 27.

10.

Erk1/2 mediates leptin receptor signaling in the ventral tegmental area.

Trinko R, Gan G, Gao XB, Sears RM, Guarnieri DJ, DiLeone RJ.

PLoS One. 2011;6(11):e27180. doi: 10.1371/journal.pone.0027180. Epub 2011 Nov 4.

11.

GAP1(IP4BP)/RASA3 mediates Galphai-induced inhibition of mitogen-activated protein kinase.

Nafisi H, Banihashemi B, Daigle M, Albert PR.

J Biol Chem. 2008 Dec 19;283(51):35908-17. doi: 10.1074/jbc.M803622200. Epub 2008 Oct 24.

12.

Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.

Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA.

Oncogene. 2007 Feb 8;26(6):813-21. Epub 2006 Aug 7.

PMID:
16909118
13.

RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.

Gailhouste L, Ezan F, Bessard A, Frémin C, Rageul J, Langouët S, Baffet G.

Int J Cancer. 2010 Mar 15;126(6):1367-77. doi: 10.1002/ijc.24950.

14.

Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1.

Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, Mitobe M, Louvi A, Velazquez H, Ishibe S, Cantley LG, Igarashi P, Somlo S.

Hum Mol Genet. 2008 Jun 1;17(11):1505-16. doi: 10.1093/hmg/ddn039. Epub 2008 Feb 7.

16.

The protease Omi cleaves the mitogen-activated protein kinase kinase MEK1 to inhibit microglial activation.

Hu Q, Li B, Xu R, Chen D, Mu C, Fei E, Wang G.

Sci Signal. 2012 Aug 21;5(238):ra61. doi: 10.1126/scisignal.2002946.

17.

Effect of inhibitors of mitogen-activated protein kinase kinase on alpha(1B)-adrenoceptor phosphorylation.

Alcántara-Hernández R, Adolfo García-Sáinz J.

Auton Autacoid Pharmacol. 2009 Jan;29(1-2):13-23. doi: 10.1111/j.1474-8673.2009.00427.x.

PMID:
19302552
18.

Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways.

Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ, Lim DS.

Stem Cells Dev. 2008 Aug;17(4):725-36. doi: 10.1089/scd.2007.0230.

PMID:
18788932
19.

Off-target effects of MEK inhibitors.

Wauson EM, Guerra ML, Barylko B, Albanesi JP, Cobb MH.

Biochemistry. 2013 Aug 6;52(31):5164-6. doi: 10.1021/bi4007644. Epub 2013 Jul 22.

20.

Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M.

Illert AL, Zech M, Moll C, Albers C, Kreutmair S, Peschel C, Bassermann F, Duyster J.

J Biol Chem. 2012 Nov 2;287(45):37997-8005. doi: 10.1074/jbc.M112.373464. Epub 2012 Sep 6.

Supplemental Content

Support Center